Company intelligence
Bambusa Therapeutics
Transforming I&I Treatment with Next-Generation Bispecific Antibodies
Biotechnology Research
BOSTON, US
22 employees
Founded 2024
2 public signals
About Bambusa Therapeutics
Bambusa Therapeutics believes the I&I field is long overdue for innovative approaches and transformative therapeutics. Since our inception, we have built a diverse portfolio of molecules and are uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions.
Verified activity
Signals from Bambusa Therapeutics
2 published signals
Research & Knowledge
Bambusa Therapeutics shared two datasets for the first time regarding the BBT002 lead program targeting IL-4Rα and IL-5.
Reported by Bambusa Therapeutics
Research & Knowledge
Bambusa Therapeutics reported that BBT002 was well tolerated with a pharmacokinetic profile supporting flexible dosing and sustained pharmacodynamic activity.
Reported by Bambusa Therapeutics